



Published in final edited form as:

Epidemiol Method. 2012 August ; 1(1): 33–54. doi:10.1515/2161-962X.1005.

Use of Individual-level Covariates to Improve Latent Class Analysis of Trypanosoma Cruzi Diagnostic Tests

Aaron W. Tustin,

Vanderbilt University School of Medicine

Dylan S. Small,

The Wharton School, University of Pennsylvania

Stephen Delgado,

School of Geography and Development, and Epidemiology Graduate Program, University of Arizona

Ricardo Castillo Neyra,

Universidad Peruana Cayetano Heredia, Lima, Peru; and Bloomberg School of Public Health, Johns Hopkins University

Manuela R. Verastegui,

Faculty of Science, Universidad Peruana Cayetano Heredia, Lima, Peru

Jenny M. Ancca Juárez,

Universidad Peruana Cayetano Heredia, Lima, Peru

Víctor R. Quispe Machaca,

Universidad Peruana Cayetano Heredia, Lima, Peru

Robert H. Gilman,

Bloomberg School of Public Health, Johns Hopkins University

Caryn Bern, and

Centers for Disease Control and Prevention

Michael Z. Levy

Department of Biostatistics and Epidemiology, University of Pennsylvania Perelman School of Medicine

Abstract

Statistical methods such as latent class analysis can estimate the sensitivity and specificity of diagnostic tests when no perfect reference test exists. Traditional latent class methods assume a constant disease prevalence in one or more tested populations. When the risk of disease varies in a known way, these models fail to take advantage of additional information that can be obtained by measuring risk factors at the level of the individual. We show that by incorporating complex field-based epidemiologic data, in which the disease prevalence varies as a continuous function of individual-level covariates, our model produces more accurate sensitivity and specificity estimates than previous methods. We apply this technique to a simulated population and to actual Chagas disease test data from a community near Arequipa, Peru. Results from our model estimate that the first-line enzyme-linked immunosorbent assay has a sensitivity of 78% (95% CI: 62–100%) and a

specificity of 100% (95% CI: 99–100%). The confirmatory immunofluorescence assay is estimated to be 73% sensitive (95% CI: 65–81%) and 99% specific (95% CI: 96–100%).

Keywords

Chagas disease; latent class analysis; *Trypanosoma cruzi*

1 Introduction

Chagas disease is a vector-borne infection caused by the protozoan parasite *Trypanosoma cruzi*. In the Americas, Chagas disease is responsible for more morbidity and mortality than any other parasitic illness (World Health Organization, 2004). Transmission of *T. cruzi* typically occurs when contaminated feces of an infected blood-feeding triatomine insect enter a human host through the insect bite site or mucous membranes (Kirchhoff et al., 2004). *T. cruzi* can also be transmitted through blood transfusions (Young et al., 2007), organ transplants (Kun et al., 2009), consumption of contaminated food (Nóbrega et al., 2009), and congenitally from mother to child (Bern et al., 2009).

Many people infected with *T. cruzi* are unaware of their infection (Tarleton et al., 2007). For this reason, various serologic tests are used to detect infected individuals and protect the blood supply in Latin America (de Andrade et al., 1996, Blejer et al., 2001, Langhi Jr et al., 2002, Pirard et al., 2005) and the United States (Centers for Disease Control and Prevention, 2007). Proper interpretation of the results of these diagnostic tests requires knowledge of the sensitivity and specificity of each assay. Unfortunately there is no “gold standard” reference test for identifying *T. cruzi* infection (Tarleton et al., 2007). Parasitologic testing, which provides a clear definition of infection and is virtually 100% specific, is insensitive (Pirard et al., 2005). Serologic assays are frequently employed, but these also lack sensitivity due to their preparation from inappropriate stages of the parasite life-cycle (Tarleton et al., 2007) or because there is a great and largely unknown variety among *T. cruzi* strains in different regions (Verani et al., 2009). Absent a perfect reference test, the performance of Chagas disease assays can only be estimated by statistical methods that compare results from two or more imperfect tests.

Latent class analysis (LCA) is a popular approach to estimating performance of diagnostic tests in the absence of a gold standard. In LCA, a probabilistic model is assumed for the relationship between the diagnostic test results and the unobserved, or latent, disease status (Hui and Walter, 1980, Qu et al., 1996, Goetghebeur et al., 2000). In this paper we focus on LCA estimates in the commonly encountered scenario in which only two conditionally independent diagnostic tests are used (Hui and Walter, 1980, Joseph et al., 1995, Staquet et al., 1981, Walter and Irwig, 1988, Basáñez et al., 2004). We also perform a sensitivity analysis to investigate the effect of conditional dependence on our parameter estimates. An unbiased estimate for the two-test case is desirable in the context of Chagas disease, where limited resources restrict the number of tests that can be performed.

If the two tests are applied to a single population, then the model has five unknown parameters (the disease prevalence, the two sensitivities, and the two specificities) but the data contain only three degrees of freedom. Because the number of parameters exceeds the number of degrees of freedom, the model is nonidentifiable and estimates can only be obtained by introducing constraints (Walter and Irwig, 1988). One constraint technique consists of a Bayesian approach in which informative prior distributions are placed on at least two parameters (Joseph et al., 1995, Basáñez et al., 2004). A problem with this

approach is that in nonidentifiable problems the posterior parameter estimates continue to be affected by the priors even as the sample size goes to infinity (Dendukuri and Joseph, 2001).

Alternatively, the two tests can be applied to two distinct populations. The model is then identifiable (provided that the two populations have sufficiently different disease prevalences) and can be solved by a maximum likelihood procedure (Hui and Walter, 1980). This approach has been used in the case of two geographically distinct populations with different prevalences (Hui and Walter, 1980, Johnson et al., 2001).

In this paper we describe a method for modeling the risk of disease as a function of multiple continuous individual-level covariates. Extended latent class models with covariates have been described previously (Huang and Bandeen-Roche, 2004, Hadgu and Qu, 1998, Dendukuri et al., 2009). Temporal covariates have been used, for example, to model test results as a function of days post infection (Engel et al., 2009) or to allow infection probability to depend on a covariate such as age (Branscum et al., 2008). We extend these analyses to consider a specific example of a population in which the probability of Chagas disease depends on several measurable temporal covariates. Our technique produces more precise parameter estimates than models that collapse the risk profile into a single binary covariate.

2 Methods

2.1 Specification of Covariate-Augmented LCA Model

We first review the likelihood computation for a two-test latent class model in which a single binary covariate separates tested individuals into two groups with different prevalences. We then show how to generalize this model to the case where the risk of disease is a continuous function of multiple covariates. Assume that two binary tests y_i ($i = 1, 2$) are applied to N individuals. Positive test results are represented by $y_i = 1$ and negative results by $y_i = 0$. Let S_i and C_i be the sensitivity and specificity, respectively, of test y_i . S_i and C_i are assumed constant across all individuals. A binary covariate is measured and used to divide the sample N into two subpopulations of size N_g (where $g = 1, 2$ and $N_1 + N_2 = N$) with distinct prevalences σ_g .

The likelihood l of the model is

$$l = \prod_{g=1}^2 \{ \sigma_g S_1 S_2 + (1 - \sigma_g)(1 - C_1)(1 - C_2) \}^{N_{g11}} \\ \times \{ \sigma_g S_1(1 - S_2) + (1 - \sigma_g)(1 - C_1)C_2 \}^{N_{g10}} \quad (1) \\ \times \{ \sigma_g(1 - S_1)S_2 + (1 - \sigma_g)C_1(1 - C_2) \}^{N_{g01}} \\ \times \{ \sigma_g(1 - S_1)(1 - S_2) + (1 - \sigma_g)C_1C_2 \}^{N_{g00}},$$

where N_{gjk} ($j, k = 0, 1$) is the number of individuals in population g with observed test results $y_1 = j$ and $y_2 = k$. This likelihood is (apart from a constant coefficient) a multinomial likelihood. The goal of traditional LCA is to find parameters σ_g , S_i , and C_i that maximize l .

We now relax the assumption of a single binary covariate. For individual n ($n = 1, \dots, N$) in the sample, let the probability of disease σ_n be a function of M measurable covariates:

$$\sigma_n = \Pr(\text{disease} | \text{covariates}) = f(\psi_1(n), \psi_2(n), \dots, \psi_M(n)) \quad (2)$$

where $\psi_m(n)$ ($m = 1, \dots, M$) is the value of the m th covariate in this subject. The covariates ψ_m may be continuous (e.g., age) or discrete. Specification of σ_n also requires a set of U risk

parameters $\beta = (\beta_1, \dots, \beta_U)$ that capture the manner in which the covariates influence the risk of disease. The functional form of σ_n is assumed to be known *a priori* and the model estimates the values of the risk parameters β . The likelihood L of this variable-risk model is

$$\begin{aligned} L &= \Pr(\text{observed data} | S_i, C_i, \beta) \\ &= \prod_{n=1}^N \{ \sigma_n S_1 S_2 + (1 - \sigma_n)(1 - C_1)(1 - C_2) \}^{\delta_{n11}} \\ &\quad \times \{ \sigma_n S_1(1 - S_2) + (1 - \sigma_n)(1 - C_1)C_2 \}^{\delta_{n10}} \\ &\quad \times \{ \sigma_n(1 - S_1)S_2 + (1 - \sigma_n)C_1(1 - C_2) \}^{\delta_{n01}} \\ &\quad \times \{ \sigma_n(1 - S_1)(1 - S_2) + (1 - \sigma_n)C_1C_2 \}^{\delta_{n00}}, \end{aligned} \quad (3)$$

where $\delta_{njk} = 1$ if individual n has test results $y_1 = j$ and $y_2 = k$, and $\delta_{njk} = 0$ otherwise. It can be shown that when σ_n is a binary function of a single covariate, equation (3) reduces to the two test/two population likelihood function. The advantage of allowing σ_n to vary across all individuals is that in some cases the disease process may best be described as a function of one or more possibly continuous variables.

2.2 Chagas Disease Data and Infection Risk from Arequipa, Peru

The development of our model was motivated by *Trypanosoma cruzi* diagnostic test data from La Joya (population 2252), a community in the Peruvian department of Arequipa. In 2008 a cross-sectional serologic and socio-demographic study was conducted in La Joya. A total of 1333 individuals participated in the survey. Fifteen subjects were excluded from the following analysis due to missing or indeterminate data, making $N = 1318$ in the final sample.

Each individual's serum was screened for *T. cruzi* infection with a commercially available enzyme-linked immunosorbent assay (ELISA) (Chagatek, Laboratorio Lemos SRL, Buenos Aires). All ELISA-positive sera and a random sample of 20% of ELISA-negative sera were also tested with an immunofluorescence assay (IFA) used as a confirmatory test (Table 1). The study protocol was approved by the institutional review boards of the Johns Hopkins Bloomberg School of Public Health and Universidad Peruana Cayetano Heredia, and analysis of data was approved by the University of Pennsylvania and Vanderbilt University.

Analysis of confirmed positive (ELISA+/IFA+) individuals showed that the yearly risk of *T. cruzi* infection in La Joya was greater prior to an insecticide spray campaign that occurred in 1995. The yearly infection risk for time lived outside the study community was also different than the risk during time spent in La Joya. The total probability of infection was best fit by an expanded catalytic model (Muench, 1959) given by

$$\sigma_n(T_{pre}(n), T_{post}(n), T_{out}(n)) = 1 - \exp(-\beta_{pre}T_{pre}(n) - \beta_{post}T_{post}(n) - \beta_{out}T_{out}(n) - K), \quad (4)$$

where the individual-level covariates are $T_{pre}(n)$, $T_{post}(n)$, and $T_{out}(n)$ (Delgado et al., 2011). T_{pre} represents the number of years lived in the study community prior to 1996 (the first full calendar year in which vector-borne transmission was interrupted); T_{post} is the number of years lived in La Joya after transmission interruption; and T_{out} is number of years lived outside the study community. For each individual, $T_{pre}(n) + T_{post}(n) + T_{out}(n) = \text{age}$. Figure (1) shows the distribution of these temporal covariates in the sampled residents of La Joya. In the definition of σ_n , the coefficients β_{pre} , β_{post} , and β_{out} represent the differential risk factors for exposure to *T. cruzi* during each residence period. The final model parameter, K , is related to the probability of time-independent transmission of *T. cruzi*, including congenital transmission.

2.2.1 Verification Bias Correction—Only 20% of ELISA-negative individuals in La Joya underwent testing with IFA. This type of missing data, in which individuals with positive outcomes on a screening test are preferentially selected for subsequent confirmatory testing, is commonly referred to as verification bias (Greenes and Begg, 1985). Verification bias is problematic in our situation because the likelihood function derived in Section 2.1 includes contributions only from individuals tested with both assays. Thus useful covariate information from 80% of ELISA-negative individuals will be discarded. Furthermore, an attempt to apply equation (3) to the subset of individuals who underwent both diagnostic tests would result in inaccurate estimates of disease prevalence and ELISA sensitivity and specificity, due to the falsely low number of ELISA-negative individuals in the sample.

Fortunately equation (3) can be modified in a straightforward manner to allow all individuals, including those who underwent only one diagnostic test, to contribute to the likelihood function. Let α represent the fraction of individuals with $y_1 = 0$ who were tested with the confirmatory test (e.g., $\alpha = 0.2$ in La Joya). There are five possible combinations of diagnostic test results whose probabilities are given by

$$\begin{aligned} P_{11}(n) &= \Pr(y_1=1, y_2=1) = \sigma_n S_1 S_2 + (1 - \sigma_n)(1 - C_1)(1 - C_2) \\ P_{10}(n) &= \Pr(y_1=1, y_2=0) = \sigma_n S_1(1 - S_2) + (1 - \sigma_n)(1 - C_1)C_2 \\ P_{01}(n) &= \Pr(y_1=0, y_2=1) = \alpha[\sigma_n(1 - S_1)S_2 + (1 - \sigma_n)C_1(1 - C_2)] \\ P_{00}(n) &= \Pr(y_1=0, y_2=0) = \alpha[\sigma_n(1 - S_1)(1 - S_2) + (1 - \sigma_n)C_1C_2] \\ P_{0X}(n) &= \Pr(y_1=0, y_2 \text{ not performed}) = (1 - \alpha)[\sigma_n(1 - S_1) + (1 - \sigma_n)C_1]. \end{aligned} \quad (5)$$

The proper covariate-augmented likelihood function, in the setting of verification bias, includes contributions from all five probabilities:

$$L = \Pr(\text{observed data} | S_i, C_i, \beta, \alpha) = \prod_{n=1}^N P_{11}(n)^{\delta_{n11}} P_{10}(n)^{\delta_{n10}} P_{01}(n)^{\delta_{n01}} P_{00}(n)^{\delta_{n00}} (P_{0X}(n))^{\delta_{n0X}}, \quad (6)$$

where $\delta_{n0X} = 1$ if individual n has $y_1 = 0$ and is not tested with assay y_2 , and $\delta_{n0X} = 0$ otherwise.

2.3 Simulation Methods

To evaluate the accuracy and robustness of our proposed method, we performed four sets of simulations (hereafter referred to as Simulations A through D). The first three simulations were based on populations with epidemiologic characteristics similar to those found in our La Joya Chagas disease survey. In each case we created a set of $N = 1318$ individuals with values of $T_{pre}(n)$, $T_{post}(n)$, and $T_{out}(n)$ identical to those in our La Joya sample (Figure 1). We then used equation (4) to assign a unique probability of infection, p_n , to each individual. We fixed the population's risk parameters at $p_{pre} = 0.01$, $p_{post} = 0.001$, $p_{out} = 0.0015$, and $K = 0.005$. For biological plausibility, these values were chosen to be similar to risk parameters estimated previously in La Joya by Delgado et al. (2011). Our choice of risk factors, combined with the measured temporal covariates, produced an overall disease prevalence of 8.5% in the simulated populations.

We next assigned a sensitivity and specificity to each diagnostic test. To measure the performance of our model over a range of diagnostic test parameters, we chose nine different combinations of S_j and C_j . Diagnostic test results for each individual were then assigned probabilistically using a random number generator. Given S_j , C_j , and an individual's unique value of p_n , the probabilities of being assigned each of the five possible combinations of test results were as given in equation (5). In the simulations with no

verification bias, there were only four possible combinations of test results. We repeated this procedure to generate a total of 1000 simulated data sets per sensitivity/specificity combination.

The purpose of the Simulation A was to compare our method to the two test/two population LCA model described in Hui and Walter (1980). The simulated diagnostic test results were created with no verification bias ($\beta = 1$). To form two populations we divided the sample into “young” and “old” groups based on whether the individual was born before or after the 1996 transmission interruption. The two-population model assumed that the prevalences were distinct in the two groups, and equation (1) was used to define the model likelihood. We minimized $-\ln(L)$ using the `nlminb` function in R 2.8.1 (R Foundation for Statistical Computing, www.r-project.org). We also fit each data set with our variable-risk model described in Section 2.1. This model assumed that the functional form of π_n was as given in equation (4). Equation (3) was used to define the model likelihood, and we used the R `nlminb` function to minimize $-\ln(L)$. Total computation time for all 9000 replicates of Simulation A was seven hours on a Linux-based machine with a single 2.0GHz Intel processor.

We performed a second set of simulations (Simulation B) to determine the effects of verification bias on our results. For this test we set $\beta = 0.2$ when creating the simulated diagnostic test data. Thus 80% of individuals with $y_1 = 0$ were not assigned a result on test y_2 . Equation (6) was used to determine the likelihood of our proposed model, and we again used the R `nlminb` function to minimize $-\ln(L)$.

Two additional simulations were designed to evaluate our model’s robustness with respect to misspecification of the functional form of π_n . In our third simulation (Simulation C) we generated diagnostic test results as above using the complex functional form of π_n given in equation (4). We then conducted our latent class analysis under the erroneous assumption of the following simpler prevalence function in which the probability of infection depends only on age: $\pi_n(A_n) = 1 - \exp(-\text{age} A_n)$, where A_n is the age of the n th individual and age is a constant age-based risk parameter.

In our final simulation (Simulation D) we created a population of 1000 individuals with a flat age distribution uniform(0, 80 years). The disease prevalence as a function of age was quadratic: $\sigma_n(A_n) = 0.00003 \times A_n^2$. The value of the age coefficient was chosen such that $\pi_n = 0$ in newborns and rises to $\pi_n = 19.2\%$ in individuals with the maximum age of 80 years. Once again we chose nine different combinations of S_j and C_j and stochastically assigned diagnostic test results to each individual. We performed our parameter estimation using a misspecified LCA model that assumed a disease prevalence $\pi_n = \text{age} A_n$ that varied linearly, rather than quadratically, with age.

2.4 Analysis of Peruvian *T. cruzi* Test Data

We analyzed the actual La Joya residence time data and *Trypanosoma cruzi* test results (Figure 1 and Table 1) with our variable-risk LCA technique. Equation (4) was used to specify the functional form of π_n . Given this expression for π_n , we constructed the model likelihood via equation (6). The `nlminb` function in R 2.8.1 was used to minimize $-\ln(L)$. In addition to computing the maximum-likelihood parameters, we employed a percentile bootstrap (1000 iterations) to compute 95% prediction intervals for each parameter (Efron and Tibshirani, 1993).

2.4.1 Relaxation of Conditional Independence Assumption—We extended our model to explore the possibility of covariance between the ELISA and IFA test results in La Joya. We specified the conditional dependence between the tests given a subject’s true

infection status via two extra parameters, $covs_{12}$ and $covc_{12}$, that represent the covariance between the tests in infected and uninfected individuals, respectively (Dendukuri and Joseph, 2001). The effect of the covariance parameters is to increase the probability of identical test results (i.e., $y_1 = y_2$) by an amount $covs_{12}$ (in infected subjects) or $covc_{12}$ (in uninfected subjects) compared with the conditionally independent case. We restricted our analysis to the scenario in which the two diagnostic tests are positively correlated.

We modified equation (6), using the methods of Dendukuri and Joseph (2001), to compute the model likelihood in the conditionally dependent case. It has been shown that two-test latent class models that allow for unknown conditional dependence are nonidentifiable even when the two diagnostic tests are applied to a large number of distinct populations (Johnson and Hanson, 2005). Because the full model is nonidentifiable, we did not attempt to maximize the likelihood function to solve for all parameters simultaneously. Instead, we performed a sensitivity analysis to determine the effect of different covariance parameters on our La Joya parameter estimates.

For any given S_i and C_i , the covariance parameters must satisfy the relations $covs_{12} \leq \min(S_1, S_2) - S_1 S_2$ and $covc_{12} \leq \min(C_1, C_2) - C_1 C_2$ (Dendukuri and Joseph, 2001). If we assume the Chagas disease diagnostic tests used in La Joya have greater than 50% sensitivity and specificity, then $covs_{12} < 0.25$ and $covc_{12} < 0.25$. Thus for our sensitivity analysis we chose eleven different fixed combinations of $covs_{12}$ and $covc_{12}$ between 0 and 0.2. For each case we obtained maximum-likelihood estimates of diagnostic test sensitivity and specificity. We also computed 95% prediction intervals for each parameter using a percentile bootstrap with 1000 iterations.

3 Results

3.1 Simulation Results

Results of Simulation A are shown in Table 2. Our model produces more accurate sensitivity and specificity estimates than the two test/two population model, with a bigger gain in accuracy for sensitivity. For all settings considered and for both sensitivity and specificity, the mean square error (bias² + variance) of our model's estimator is at least as small as that of the two test/two population model. Our model's sensitivity estimate is considerably less biased than that of the two test/two population model when the true sensitivity is 95%. For other settings, both models estimate sensitivity with low bias. The standard deviation of our model's estimate of sensitivity is more than 25% smaller than that of the two test/two population model in 8 of 9 settings for both S_1 and S_2 . With respect to specificity, the bias of our model's estimates and those of the two test/two population model are similar and small in all settings. The standard deviation of our model's specificity estimate is always smaller than that of the two test/two population model.

Table 3 shows results from Simulation B. Compared to "Model1" from Simulation A (Table 2), in which there is no verification bias, the sensitivity estimates from Simulation B have similar bias when the true sensitivity is 70%. Sensitivity estimates from Simulation B are slightly more biased when the true sensitivity is at least 85%. Standard deviations of the sensitivity estimates from Simulation B are 28–83% higher than those of Simulation A. The biases and standard deviations of the specificity estimates from Simulation B are similar to those of Simulation A across all values of true specificity.

Results of Simulations C and D (Tables 4 and 5) demonstrate that when the LCA model's assumed prevalence function differs from truth, the bias and the variance of the estimated diagnostic test parameters increase. However, the true values of S_i and C_i are still contained within the model's 95% confidence intervals for all combinations of sensitivity and

specificity considered. Furthermore, in these populations with low disease prevalence, even the misspecified models estimate C_I with small bias. In Table 5 we also present the mean value of $-\ln(L)$ for each simulation. In 8 of 9 simulations the properly specified quadratic model has a larger likelihood.

3.2 Results of Analysis of La Joya *T. cruzi* Data

Parameter estimates from our covariate-augmented LCA model applied to actual Chagas disease diagnostic test data from La Joya, Peru, are shown in Table 6. All estimates were calculated using the likelihood function with verification bias correction described in Section 2.2.1. The estimated specificities of ELISA and IFA in La Joya are nearly 100%. In contrast, the point estimates of the sensitivities of both tests are less than 80%. In the case of ELISA, however, the uncertainty is large enough that a sensitivity as high as 100% cannot be ruled out.

The model's estimates of the risk parameters ρ_{pre} , ρ_{post} , ρ_{out} , and K confirm that the yearly risk of *T. cruzi* infection prior to the insecticide spray campaign (ρ_{pre}) was much greater than the post-spray risk, which was indistinguishable from zero. The estimated infection prevalence in the population (found by averaging ρ_n across all subjects) is 13.4%.

The estimated positive predictive values of ELISA and IFA in patients who tested positive on those assays are high (Figures 2A and 2B). Because of the tests' high specificities in this population, most positive results represent true infections. Furthermore, using IFA to confirm positive ELISA results does not often significantly change the posterior probability of infection (Figures 2C and 2D).

The estimated sensitivity and specificity of ELISA and IFA in La Joya are reduced when the diagnostic tests are assumed to be conditionally dependent (Table 7). The sensitivities of ELISA and IFA are as low as 67% and 58%, respectively, when $covs_{12}$ and $covc_{12}$ are at most 0.05. Larger covariances of up to 0.1 produce estimates of ELISA sensitivity as low as 47% and IFA sensitivity as low as 38%. With regards to specificity, the model predicts that ELISA and IFA are at least 88% specific even if the covariance between the tests is as high as 0.1. Covariances larger than 0.1 produce even smaller sensitivity and specificity estimates.

4 Discussion

When estimating the sensitivity and specificity of diagnostic tests, the analyzed test results are often stripped of epidemiologic context. By treating all identical patterns of results as equivalent, algorithms such as latent class analysis may ignore vital information about differences between tested individuals. Many previous attempts to incorporate epidemiologic information into LCA have utilized two-tiered risk stratifications based on geographic location (Branscum et al., 2005, Hui and Walter, 1980, Johnson et al., 2001). If the probability of disease varies in a more complex manner, we show that careful measurement of individual-level risk allows LCA to estimate diagnostic test parameters more accurately.

With respect to Chagas disease in La Joya, Arequipa, Peru, our model estimates the specificity of the commercial Chagatek ELISA to be 100% (95% CI: 99–100%). Published Chagatek specificities from other sources range from 87.31–100% (Blejer et al., 2001, Caballero et al., 2007). Our estimate is at the high end of this range. We estimate the specificity of IFA to be 99% (95% CI: 96–100%). The specificity of *T. cruzi* serum tests can be lowered by cross-reactivity with *Leishmania* spp. or *Trypanosoma rangeli* (Caballero et al., 2007, Malchiodi et al., 1994). Thus the near-perfect specificity that we observe in La

Joya may reflect the fact that neither *T. rangeli* nor *Leishmania* spp. is endemic to the area (Levy et al., 2009, Lucas et al., 1998).

Our estimate of ELISA sensitivity is 78% (95% CI: 62–100%), much lower than other published estimates which range from 99.67–100% (Blejer et al., 2001, Caballero et al., 2007), although the upper end of our confidence interval includes these values. We also find a low sensitivity of 73% (95% CI: 65–81%) in the confirmatory IFA test. Our low sensitivity estimates corroborate a recent report that recombinant antigen-based rapid tests for Chagas disease exhibit much lower sensitivity in Arequipa than in Bolivia (Verani et al., 2009). The decreased sensitivities observed in Arequipa may be due to parasite heterogeneity, as the species *T. cruzi* is known to include various strains whose different antigenic properties may cause geographic variations in the performance of antigen-based diagnostic tests (Verani et al., 2009, Campbell et al., 2004).

Our simulations, as well as our analysis of actual Chagas disease test results, produce sensitivity estimates whose confidence intervals are much wider than those of the specificity estimates. Although verification bias has been shown to increase the variability of parameter estimates, our Simulation A (Table 2), in which all individuals underwent both diagnostic tests, demonstrates that the uncertainty in our sensitivity estimates is not entirely due to verification bias. Rather, our sensitivity estimates are uncertain because of the low disease prevalence in our samples. When prevalence is low, there are few subjects with positive test results, and thus it is difficult to estimate the rate of true positives (i.e., sensitivity) (Joseph et al., 1995).

Use of our technique requires a mathematical description of risk variability. In our study population, we chose a biologically plausible risk model that fits the observed test results better than several other candidate functions (Delgado et al., 2011). However, the true risk function is always unknowable, and even the best-fit model may not perfectly represent reality. Thus when applying our method to other disease states, care should be taken to verify the suitability of the proposed risk model. One way to do so is to create various risk functions and choose the one that maximizes a model selection criterion such as the Akaike Information Criterion (Akaike, 1974). Our simulations of misspecified models (Tables 4 and 5) show that in cases where the true risk function is unknown, a selection criterion based on the LCA likelihood could be used to choose between candidate prevalence functions.

Our primary results assume conditional independence between ELISA and IFA, but we have also explored the sensitivity of our estimates to this assumption. Addition of conditional dependence to the model reduces the estimated diagnostic test sensitivity and specificity. The sensitivity estimates are affected more than the specificity estimates. Although we cannot rule out the possibility of conditional dependence between ELISA and IFA, there is reason to believe that any covariance is likely to be small. A previous latent class analysis of Chagas disease diagnostic tests (including ELISA and IFA) found that a conditional independence model fit best (Pirard et al., 2005). And the choice of a conditional independence model is further justified by the observation, mentioned above, that Arequipa lacks cross-reacting organisms that could cause correlated false-positive results on multiple assays.

Similarly, throughout this paper we have assumed that diagnostic test sensitivity and specificity are constant across all subpopulations. Although beyond the scope of our current analysis, this assumption could in principle be relaxed. The model presented here could easily be expanded to include covariate effects on sensitivity and specificity, in addition to disease prevalence.

The observed lack of sensitivity of *T. cruzi* diagnostic tests in Arequipa is clinically problematic. Current protocols, which require two consecutive positive test results on different assays before treatment is initiated, exclude many infected individuals from consideration for pharmacological therapy. The magnitude of the undercount can be estimated by noting that our model predicts a *T. cruzi* infection prevalence of 13.4% in La Joya. In contrast, a much lower prevalence estimate of $101/1318 = 7.7\%$ is produced when only ELISA+/IFA+ individuals are considered to be infected. This latter case definition was used in a previous analysis of *T. cruzi* transmission in La Joya, which explains why the predominant risk parameters measured in that study were roughly half as large as our estimates (Delgado et al., 2011).

Because the specificity of ELISA is very high in Arequipa, using IFA (or another test) to confirm positive ELISA results does little more than increase the rate of false negative. ELISA-positive individuals almost certainly represent true cases (Figure 2). The probability of infection remains high even if the subsequent IFA is negative. These findings are consistent with a recent report that ELISA+/IFA- individuals in Arequipa are geographically clustered around confirmed (ELISA+/IFA+) cases, making it likely that individuals with discordant results are in fact infected with *T. cruzi* (Levy et al., 2009). We suggest that clinical resources could be saved by reconsidering the need for confirmatory tests in ELISA-positive patients in settings with a reasonably high probability of infection. By analyzing diagnostic tests in context it may be possible to reduce expenses, which is particularly important when diagnosing neglected tropical diseases.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

We gratefully acknowledge the contributions of Dr. Juan Cornejo del Carpio, Dr. César Naquira, and Fernando Malaga. The Tropical Medicine Research Center (TMRC) Peru working group performed field-based collection of seroprevalence and epidemiologic data as well as laboratory-based diagnostic analyses. The following organizations facilitated the implementation of this study: Ministerio de Salud del Perú (MINSA), Dirección General de Salud de las Personas (DGSP), Estrategia Sanitaria Nacional de Prevención y Control de Enfermedades Metaxénicas y Otras Transmitidas por Vectores (ESNPCEMOTVS), Dirección General de Salud Ambiental (DIGESA); Gobierno Regional de Arequipa; Gerencia Regional de Salud de Arequipa (GRSA); Pan American Health Organization (PAHO); and Canadian International Development Agency (CIDA). We thank the communities of Las Dunas y Primavera, Los Laureles, Rio de Janeiro, and Villa La Joya for their participation in this study. Funding This work was supported by the National Institutes of Health (5P50 AI074285-03 and 04, 3K01AI079162-02S1 to M.Z.L., 5 T37 MD001427 to S.D.), the National Institute of Allergy and Infectious Diseases (1K01AI079162-03 to M.Z.L.) and the American Society of Tropical Medicine and Hygiene (Benjamin Kean Fellowship to A.W.T.).

References

- Akaike H. A new look at the statistical model identification. *IEEE Transactions on Automatic Control*. 1974; 19:716–723.
- Basáñez MG, Marshall C, Carabin H, Gyorkos T, Joseph L. Bayesian statistics for parasitologists. *Trends in Parasitology*. 2004; 20:85–91. [PubMed: 14747022]
- Bern C, Verastegui M, Gilman RH, Lafuente C, Galdos-Cardenas G, Calderon M, Pacori J, Del Carmen Abastoflor M, Aparicio H, Brady MF, Ferrufino L, Angulo N, Marcus S, Sterling C, Maguire JH. Congenital *Trypanosoma cruzi* transmission in Santa Cruz, Bolivia. *Clinical Infectious Diseases*. 2009; 49:1667–1674. [PubMed: 19877966]
- Blejer JL, Saguier MC, Salamone HJ. Antibodies to *Trypanosoma cruzi* among blood donors in Buenos Aires, Argentina. *International Journal of Infectious Diseases*. 2001; 5:89–93. [PubMed: 11468104]

- Branscum AJ, Gardner IA, Johnson WO. Estimation of diagnostic-test sensitivity and specificity through Bayesian modeling. *Preventive Veterinary Medicine*. 2005; 68:145–163. [PubMed: 15820113]
- Branscum AJ, Johnson WO, Hanson TE, Gardner IA. Bayesian semiparametric ROC curve estimation and disease diagnosis. *Statistics in Medicine*. 2008; 27:2474–2496. [PubMed: 18300333]
- Caballero ZC, Sousa OE, Marques WP, Saez-Alquezar A, Umezawa ES. Evaluation of serological tests to identify *Trypanosoma cruzi* infection in humans and determine cross-reactivity with *Trypanosoma rangeli* and *Leishmania* spp. *Clinical and Vaccine Immunology*. 2007; 14:1045–1049. [PubMed: 17522327]
- Campbell DA, Westenberger SJ, Sturm NR. The determinants of Chagas disease: connecting parasite and host genetics. *Current Molecular Medicine*. 2004; 4:549–562. [PubMed: 15357207]
- Centers for Disease Control and Prevention. Blood donor screening for Chagas disease—United States, 2006–2007. *MMWR Morbidity and Mortality Weekly Report*. 2007; 56:141–143. [PubMed: 17318113]
- de Andrade AL, Zicker F, de Oliveira RM, Almeida Silva S, Luquetti A, Travassos LR, Almeida IC, de Andrade SS, de Andrade JG, Martelli CM. Randomised trial of efficacy of benznidazole in treatment of early *Trypanosoma cruzi* infection. *Lancet*. 1996; 348:1407–1413. [PubMed: 8937280]
- Delgado S, Castillo Neyra R, Quispe Machaca VR, Ancca Juárez J, Chou Chu L, Verastegui MR, Moscoso Apaza GM, Bocángel CD, Tustin AW, Sterling CR, Comrie AC, Náquira C, Cornejo del Carpio JG, Gilman RH, Bern C, Levy MZ. A history of Chagas disease transmission, control, and re-emergence in peri-rural La Joya, Peru. *PLoS Neglected Tropical Diseases*. 2011; 5:e970. [PubMed: 21364970]
- Dendukuri N, Hadgu A, Wang L. Modeling conditional dependence between diagnostic tests: a multiple latent variable model. *Statistics in Medicine*. 2009; 28:441–461. [PubMed: 19067379]
- Dendukuri N, Joseph L. Bayesian approaches to modeling the conditional dependence between multiple diagnostic tests. *Biometrics*. 2001; 57:158–167. [PubMed: 11252592]
- Efron, B.; Tibshirani, RJ. *An Introduction to the Bootstrap*. New York: Chapman & Hall; 1993.
- Engel B, Backer J, Buist W. *Journal of Agricultural, Biological, and Environmental Statistics*. 2009; 15:83–100.
- Goetghebeur E, Liinev J, Boelaert M, Van der Stuyf P. Diagnostic test analyses in search of their gold standard: latent class analyses with random effects. *Statistical Methods in Medical Research*. 2000; 9:231–248. [PubMed: 11084706]
- Greenes RA, Begg CB. Assessment of diagnostic technologies. Methodology for unbiased estimation from samples of selectively verified patients. *Investigative Radiology*. 1985; 20:751–756. [PubMed: 3835974]
- Hadgu A, Qu Y. A biomedical application of latent class models with random effects. *Applied Statistics*. 1998; 47:603–616.
- Huang G-H, Bandeen-Roche K. Latent class regression with covariate effects on underlying and measured variables. *Psychometrika*. 2004; 69:5–32.
- Hui SL, Walter SD. Estimating the error rates of diagnostic tests. *Biometrics*. 1980; 36:167–171. [PubMed: 7370371]
- Johnson WO, Gastwirth JL, Pearson LM. Screening without a “gold standard”: the Hui-Walter paradigm revisited. *American Journal of Epidemiology*. 2001; 153:921–924. [PubMed: 11323324]
- Johnson WO, Hanson TE. Comment: On model expansion, model contraction, identifiability and prior information: two illustrative scenarios involving mismeasured variables. *Statistical Science*. 2005; 20:131–134.
- Jones G, Johnson WO, Daan Vink W. Evaluating a continuous biomarker for infection by using observed disease status with covariate effects on disease. *Journal of the Royal Statistical Society, Series C (Applied Statistics)*. 2009; 58:705–717.
- Joseph L, Gyorkos TW, Coupal L. Bayesian estimation of disease prevalence and the parameters of diagnostic tests in the absence of a gold standard. *American Journal of Epidemiology*. 1995; 141:263–272. [PubMed: 7840100]

- Kirchhoff LV, Weiss LM, Wittner M, Tanowitz HB. Parasitic diseases of the heart. *Frontiers in Bioscience*. 2004; 9:706–723. [PubMed: 14766402]
- Kun H, Moore A, Mascola L, Steurer F, Lawrence G, Kubak B, Radhakrishna S, Herron R, Mone T, Hunter R, Kuehnert M. Transmission of *Trypanosoma cruzi* by heart transplantation. *Clinical Infectious Diseases*. 2009; 48:1534–1540. [PubMed: 19400748]
- Langhi M Jr, Bordin JO, Castelo A, Walter SD, Moraes-Souza H, Stumpf RJ. The application of latent class analysis for diagnostic test validation of chronic *Trypanosoma cruzi* infection in blood donors. *Brazilian Journal of Infectious Diseases*. 2002; 6:181–187. [PubMed: 12204185]
- Levy MZ, Bowman NM, Kawai V, Plotkin JB, Waller LA, Cabrera L, Steurer F, Seitz AE, Pinedo-Cancino VV, Cornejo del Carpio JG, Cordova Benzaquen E, McKenzie FE, Maguire JH, Gilman RH, Bern C. Spatial patterns in discordant diagnostic test results for Chagas disease: links to transmission hotspots. *Clinical Infectious Diseases*. 2009; 48:1104–1106. [PubMed: 19278335]
- Lucas CM, Franke ED, Cachay MI, Tejada A, Cruz ME, Kreutzer RD, Barker DC, McCann SH, Watts DM. Geographic distribution and clinical description of leishmaniasis cases in Peru. *American Journal of Tropical Medicine and Hygiene*. 1998; 59:312–317. [PubMed: 9715953]
- Malchiodi EL, Chiamonte MG, Taranto NJ, Zwirner NW, Margni RA. Cross-reactivity studies and differential serodiagnosis of human infections caused by *Trypanosoma cruzi* and *Leishmania* spp; use of immunoblotting and ELISA with a purified antigen (Ag163B6). *Clinical and Experimental Immunology*. 1994; 97:417–423. [PubMed: 8082296]
- Muench, H. *Catalytic Models in Epidemiology*. Cambridge, Massachusetts: Harvard University Press; 1959.
- Nóbrega AA, Garcia MH, Tatto E, Obara MT, Costa E, Sobel J, Araujo WN. Oral transmission of Chagas disease by consumption of açai palm fruit, Brazil. *Emerging Infectious Diseases*. 2009; 15:653–655. [PubMed: 19331764]
- Pirard M, Iihoshi N, Boelaert M, Basanta P, López F, Van der Stuyft P. The validity of serologic tests for *Trypanosoma cruzi* and the effectiveness of transfusional screening strategies in a hyperendemic region. *Transfusion*. 2005; 45:554–561. [PubMed: 15819677]
- Qu Y, Tan M, Kutner M. Random effects models in latent class analysis for evaluating accuracy of diagnostic tests. *Biometrics*. 1996; 52:797–810. [PubMed: 8805757]
- Staquet M, Rozenzweig M, Lee YJ, Muggia FM. Methodology for the assessment of new dichotomous diagnostic tests. *Journal of Chronic Diseases*. 1981; 34:599–610. [PubMed: 6458624]
- Tarleton RL, Reithinger R, Urbina JA, Kitron U, Gürtler RE. The challenges of Chagas Disease—grim outlook or glimmer of hope. *PLoS Medicine*. 2007; 4:e332. [PubMed: 18162039]
- Verani JR, Seitz A, Gilman RH, LaFuente C, Galdos-Cardenas G, Kawai V, de LaFuente E, Ferrufino L, Bowman NM, Pinedo-Cancino V, Levy MZ, Steurer F, Todd CW, Kirchhoff LV, Cabrera L, Verastegui M, Bern C. Geographic variation in the sensitivity of recombinant antigen-based rapid tests for chronic *Trypanosoma cruzi* infection. *American Journal of Tropical Medicine and Hygiene*. 2009; 80:410–415. [PubMed: 19270291]
- Walter SD, Irwig LM. Estimation of test error rates, disease prevalence and relative risk from misclassified data: a review. *Journal of Clinical Epidemiology*. 1988; 41:923–937. [PubMed: 3054000]
- World Health Organization. [Accessed March 3, 2010] The world health report 2004: changing history. 2004. Available at: <http://www.who.int/whr/2004/en/>
- Young C, Losikoff P, Chawla A, Glasser L, Forman E. Transfusion-acquired *Trypanosoma cruzi* infection. *Transfusion*. 2007; 47:540–544. [PubMed: 17319837]




Figure 1.

Residence time history data for individuals tested for *T. cruzi* infection in La Joya, Arequipa, Peru. The 1318 subjects are ordered by increasing age on the x-axis. Transmission interruption due to insecticide spraying is presumed to have occurred twelve years prior to data collection, and thus $T_{post} = 12$ for all subjects.




Figure 2. Covariate-augmented latent class estimates of positive predictive values of ELISA and IFA in La Joya, Arequipa, Peru. **(A)** and **(B)** Positive predictive value of each diagnostic test when used alone. **(C)** and **(D)** Positive predictive value of both possible outcomes when IFA was used as a confirmatory test in ELISA-positive individuals.

Table 1Frequency of observed *Trypanosoma cruzi* diagnostic test results in La Joya, Peru.

	IFA+	IFA-	IFA not performed	Total
ELISA+	101	39	0	140
ELISA-	8	226	944	1178
Total	109	265	944	1318

Table 2

Results of Simulation A. True values of each diagnostic test parameter are compared to estimates from a covariate-augmented LCA model with a variable risk function (“Model1”) and a model that used an age cutoff to divide the population into two groups with different prevalences (“Model2”). Each parameter estimate is presented as mean ± standard deviation (95% CI) of 1000 simulations. All values are reported as percents.

Model1		True		Estimated		True		Estimated	
S ₁	S ₂	C ₁	C ₂	S ₁	S ₂	C ₁	C ₂	S ₁	S ₂
70	69 ± 17.4 (40,100)	70	71 ± 2.6 (67,77)	70	69 ± 17.2 (42,100)	70	71 ± 2.5 (67,77)	70	68 ± 22.4 (37,100)
70	69 ± 7.2 (56,84)	70	70 ± 1.7 (67,74)	95	88 ± 13.6 (57,100)	95	95 ± 1.6 (93,99)	95	82 ± 20 (42,100)
70	71 ± 9.7 (53,92)	95	95 ± 1 (93,97)	70	71 ± 9.8 (53,93)	95	95 ± 1 (93,97)	95	72 ± 14.6 (48,100)
85	85 ± 10.5 (65,100)	85	85 ± 1.5 (82,88)	85	84 ± 10.3 (64,100)	85	85 ± 1.5 (83,88)	85	83 ± 15.1 (54,100)
85	85 ± 7.1 (71,100)	85	85 ± 1.2 (83,88)	95	93 ± 8.2 (74,100)	95	95 ± 1 (93,97)	95	89 ± 12.8 (61,100)
85	85 ± 7.5 (71,100)	95	95 ± 0.9 (93,97)	85	85 ± 7.8 (70,100)	95	95 ± 0.9 (93,97)	85	85 ± 11.2 (64,100)
95	92 ± 8.8 (71,100)	70	71 ± 2 (67,75)	95	91 ± 9.4 (69,100)	70	71 ± 1.9 (67,75)	95	86 ± 14.5 (57,100)
95	93 ± 7.3 (76,100)	85	85 ± 1.4 (83,88)	95	93 ± 7.5 (76,100)	85	85 ± 1.3 (83,88)	95	89 ± 11.9 (63,100)
95	94 ± 5.3 (82,100)	95	95 ± 0.8 (94,97)	95	94 ± 5.4 (82,100)	95	95 ± 0.8 (94,97)	95	92 ± 8.1 (75,100)
Model2									
70	69 ± 22.3 (37,100)	70	73 ± 7.2 (66,100)	70	68 ± 22.4 (37,100)	70	72 ± 6 (66,95)	70	72 ± 6 (66,95)
70	70 ± 10.1 (53,94)	70	71 ± 2.3 (67,76)	95	82 ± 20 (42,100)	95	95 ± 2.1 (92,100)	95	95 ± 2.1 (92,100)
70	72 ± 14.6 (48,100)	95	95 ± 1.4 (93,98)	70	72 ± 14.6 (48,100)	95	95 ± 1.4 (93,98)	95	95 ± 1.4 (93,98)
85	82 ± 15.1 (54,100)	85	86 ± 2.2 (82,91)	85	83 ± 15.1 (53,100)	85	86 ± 2.2 (82,91)	85	86 ± 2.2 (82,91)
85	84 ± 10.3 (66,100)	85	86 ± 1.7 (83,90)	95	89 ± 12.8 (61,100)	95	95 ± 1.4 (93,98)	95	95 ± 1.4 (93,98)
85	85 ± 11.2 (64,100)	95	95 ± 1.3 (93,98)	85	85 ± 11.5 (63,100)	95	95 ± 1.2 (93,98)	95	95 ± 1.2 (93,98)
95	86 ± 14.5 (57,100)	70	72 ± 3.6 (67,80)	95	86 ± 14.9 (56,100)	70	72 ± 3.5 (67,81)	70	72 ± 3.5 (67,81)
95	89 ± 11.9 (63,100)	85	86 ± 2 (83,90)	95	89 ± 11.5 (65,100)	85	86 ± 2 (83,91)	85	86 ± 2 (83,91)
95	92 ± 8.1 (74,100)	95	95 ± 1.1 (94,98)	95	92 ± 8.1 (75,100)	95	95 ± 1.1 (93,98)	95	95 ± 1.1 (93,98)

Results of Simulation B: LCA in a La Joya-like population with verification bias ($\alpha = 0.2$). True values of each diagnostic test parameter are compared to estimates from a covariate-augmented LCA model with a variable risk function. Each parameter estimate is presented as mean \pm standard deviation (95% CI) of 1000 simulations. All values are reported as percents.

Table 3

True	Estimated	True	Estimated	True	Estimated	True	Estimated
S_1	S_1	C_1	C_1	S_2	S_2	C_2	C_2
70	70 \pm 22.2 (38,100)	70	72 \pm 2.8 (67,79)	70	68 \pm 18.1 (40,100)	70	73 \pm 4.5 (65,83)
70	69 \pm 13.2 (48,100)	70	71 \pm 1.6 (67,74)	95	87 \pm 14.9 (55,100)	95	96 \pm 2.6 (91,100)
70	70 \pm 17.5 (41,100)	95	95 \pm 1 (93,97)	70	70 \pm 10.3 (52,94)	95	96 \pm 2.1 (91,100)
85	82 \pm 16.3 (51,100)	85	85 \pm 1.6 (82,89)	85	83 \pm 10.8 (63,100)	85	86 \pm 3 (81,92)
85	84 \pm 12.1 (62,100)	85	85 \pm 1.3 (83,88)	95	93 \pm 8.2 (74,100)	95	95 \pm 1.9 (92,100)
85	84 \pm 13.3 (58,100)	95	95 \pm 0.9 (93,97)	85	85 \pm 7.9 (69,100)	95	95 \pm 1.9 (92,99)
95	85 \pm 14.2 (57,100)	70	71 \pm 2.1 (67,76)	95	89 \pm 10.5 (66,100)	70	72 \pm 4.2 (65,82)
95	89 \pm 12.3 (63,100)	85	85 \pm 1.4 (83,88)	95	92 \pm 7.8 (75,100)	85	86 \pm 2.8 (81,92)
95	92 \pm 9.5 (70,100)	95	95 \pm 0.8 (94,97)	95	94 \pm 5.5 (82,100)	95	96 \pm 1.7 (92,99)

Table 4

Results of Simulation C: LCA model with misspecified prevalence function that depends on age only. True values of each diagnostic test parameter are compared to estimates from a misspecified covariate-augmented LCA model. There was no verification bias ($\alpha = 1$). Each parameter estimate is presented as mean \pm standard deviation (95% CI) of 1000 simulations. All values are reported as percents.

	True	Estimated	True	Estimated	True	Estimated	True	Estimated
S_1	S_1	C_1	C_1	S_2	S_2	C_2	C_2	C_2
70	69 \pm 19.1 (39,100)	70	71 \pm 2.6 (67,76)	70	69 \pm 18.9 (39,100)	70	71 \pm 2.4 (67,76)	70
70	67 \pm 6.9 (55,82)	70	71 \pm 1.7 (68,75)	95	88 \pm 16.3 (51,100)	95	96 \pm 1.3 (94,99)	95
70	67 \pm 12.3 (48,99)	95	95 \pm 1.2 (93,98)	70	67 \pm 11.8 (47,97)	95	96 \pm 1.2 (93,98)	95
85	80 \pm 13.1 (58,100)	85	86 \pm 1.8 (83,90)	85	81 \pm 13 (58,100)	85	86 \pm 1.8 (83,90)	85
85	81 \pm 8.5 (67,100)	85	86 \pm 1.5 (83,89)	95	91 \pm 10.6 (67,100)	95	96 \pm 1.2 (93,98)	95
85	82 \pm 9.9 (64,100)	95	95 \pm 1.1 (93,98)	85	83 \pm 10 (65,100)	95	95 \pm 1.1 (93,98)	95
95	88 \pm 11.5 (64,100)	70	71 \pm 2.1 (68,76)	95	88 \pm 11.1 (66,100)	70	71 \pm 2.1 (68,76)	70
95	90 \pm 9.8 (70,100)	85	86 \pm 1.6 (83,89)	95	90 \pm 9.6 (70,100)	85	86 \pm 1.6 (83,89)	85
95	92 \pm 7.4 (76,100)	95	95 \pm 1 (94,97)	95	93 \pm 7.3 (77,100)	95	95 \pm 1 (94,97)	95

Table 5

Results of Simulation D. The true prevalence function in the simulated populations was quadratic with age. Covariate-augmented LCA models that assumed both linear and quadratic prevalence functions were then fitted to the diagnostic test data. There was no verification bias ($\beta = 1$). Each parameter estimate is presented as mean \pm standard deviation (95% CI) of 1000 simulations. All values are reported as percents. The negative of the natural logarithm of the model likelihood is also reported as mean \pm standard deviation.

Linear model											
True	Estimated	True	Estimated	True	Estimated	True	Estimated	True	Estimated	True	Estimated
S_1	S_1	C_1	C_1	S_2	S_2	C_2	C_2	S_2	S_2	C_2	$-\ln(L)$
70	66 \pm 22.2 (36,100)	70	71 \pm 2.6 (66,77)	70	67 \pm 22.6 (35,100)	70	71 \pm 2.7 (67,77)	70	71 \pm 2.7 (67,77)	70	1255 \pm 16
70	63 \pm 8.6 (49,82)	70	71 \pm 2.2 (67,76)	95	79 \pm 22.9 (36,100)	95	97 \pm 1.3 (94,99)	95	97 \pm 1.3 (94,99)	95	946 \pm 23
70	64 \pm 15.8 (41,100)	95	96 \pm 1.3 (93,98)	70	64 \pm 15.5 (40,100)	95	96 \pm 1.3 (93,98)	95	96 \pm 1.3 (93,98)	95	568 \pm 29
85	76 \pm 16.1 (49,100)	85	86 \pm 1.9 (83,91)	85	76 \pm 16.5 (48,100)	85	86 \pm 2 (83,90)	85	86 \pm 2 (83,90)	85	956 \pm 27
85	78 \pm 11.5 (59,100)	85	86 \pm 1.8 (83,90)	95	85 \pm 15.5 (54,100)	95	96 \pm 1.3 (94,99)	95	96 \pm 1.3 (94,99)	95	777 \pm 30
85	80 \pm 13.9 (55,100)	95	96 \pm 1.2 (93,98)	85	79 \pm 13.2 (57,100)	95	96 \pm 1.3 (93,98)	95	96 \pm 1.3 (93,98)	95	578 \pm 30
95	84 \pm 14.7 (56,100)	70	72 \pm 2.4 (68,77)	95	83 \pm 14.9 (55,100)	70	72 \pm 2.4 (68,77)	70	72 \pm 2.4 (68,77)	70	1268 \pm 16
95	85 \pm 13.7 (59,100)	85	86 \pm 1.9 (83,90)	95	84 \pm 14.2 (57,100)	85	86 \pm 1.9 (83,90)	85	86 \pm 1.9 (83,90)	85	963 \pm 27
95	89 \pm 10.9 (66,100)	95	96 \pm 1.2 (94,98)	95	89 \pm 10.3 (67,100)	95	96 \pm 1.1 (94,98)	95	96 \pm 1.1 (94,98)	95	578 \pm 32
Quadratic model											
70	72 \pm 21.7 (37,100)	70	70 \pm 2 (66,74)	70	72 \pm 21.9 (37,100)	70	70 \pm 2 (66,75)	70	70 \pm 2 (66,75)	70	1255 \pm 16
70	70 \pm 9.3 (54,90)	70	71 \pm 1.8 (67,75)	95	85 \pm 18.8 (44,100)	95	95 \pm 1.1 (93,97)	95	95 \pm 1.1 (93,97)	95	944 \pm 23
70	72 \pm 14.1 (49,100)	95	95 \pm 1 (93,97)	70	71 \pm 13.8 (49,100)	95	95 \pm 1.1 (93,97)	95	95 \pm 1.1 (93,97)	95	566 \pm 29
85	84 \pm 13.3 (57,100)	85	85 \pm 1.5 (83,88)	85	84 \pm 13.6 (57,100)	85	85 \pm 1.6 (82,88)	85	85 \pm 1.6 (82,88)	85	954 \pm 27
85	85 \pm 9.6 (68,100)	85	85 \pm 1.4 (83,88)	95	90 \pm 11.6 (63,100)	95	95 \pm 1.1 (93,97)	95	95 \pm 1.1 (93,97)	95	774 \pm 30
85	85 \pm 11.1 (64,100)	95	95 \pm 1 (93,97)	85	85 \pm 10.6 (65,100)	95	95 \pm 1 (93,97)	95	95 \pm 1 (93,97)	95	575 \pm 31
95	90 \pm 12.2 (62,100)	70	70 \pm 1.9 (67,74)	95	89 \pm 12.5 (61,100)	70	70 \pm 1.9 (67,74)	70	70 \pm 1.9 (67,74)	70	1267 \pm 16
95	91 \pm 10.1 (68,100)	85	85 \pm 1.5 (83,88)	95	91 \pm 10.4 (68,100)	85	85 \pm 1.4 (83,88)	85	85 \pm 1.4 (83,88)	85	961 \pm 27
95	93 \pm 8 (76,100)	95	95 \pm 1 (93,97)	95	93 \pm 7.7 (75,100)	95	95 \pm 0.9 (94,97)	95	95 \pm 0.9 (94,97)	95	574 \pm 32

Table 6

Parameter estimates and bootstrap confidence intervals from our latent class model with continuous covariates, applied to *T. cruzi* test data from La Joya, Peru.

Parameter	Model estimate (95% CI)
ELISA sensitivity (S_1)	78% (62–100%)
ELISA specificity (C_1)	100% (99–100%)
IFA sensitivity (S_2)	73% (65–81%)
IFA specificity (C_2)	99% (96–100%)
Pre-spray risk parameter (ρ_{pre})	0.019 (0.013–0.026)
Post-spray risk parameter (ρ_{post})	0 (0–0.0005)
Parameter for risk outside La Joya (ρ_{out})	0.0031 (0.0016–0.0050)
Congenital transmission parameter (K)	0.0047 (0–0.014)

Table 7

Analysis of the effect of conditional dependence on estimates of diagnostic test performance in La Joya. We maximized the likelihood of the model for nine different sets of covariances (column 1). Columns 2–5 give the maximum-likelihood estimates and bootstrap 95% confidence intervals of the diagnostic test sensitivities and specificities (expressed as percents) when these covariances are assumed.

	S_1	C_1	S_2	C_2
$(covs_{12}, covc_{12})$	(95% CI)	(95% CI)	(95% CI)	(95% CI)
(0, 0)	78 (62,100)	100 (99,100)	73 (65,81)	99 (96,100)
(0, 0.05)	74 (56,100)	94 (94,95)	65 (55,81)	93 (91,95)
(0, 0.1)	55 (44,100)	89 (88,89)	54 (42,79)	89 (85,89)
(0.05, 0)	71 (55,93)	100 (99,100)	66 (58,75)	99 (96,100)
(0.05, 0.05)	67 (48,93)	94 (94,95)	58 (49,75)	93 (91,95)
(0.05, 0.1)	49 (36,91)	88 (88,89)	46 (35,76)	88 (85,89)
(0.1, 0)	63 (46,86)	100 (99,100)	57 (48,71)	99 (95,100)
(0.1, 0.05)	60 (43,84)	94 (94,95)	50 (41,70)	93 (90,95)
(0.1, 0.1)	47 (36,83)	88 (87,89)	38 (29,68)	88 (85,89)
(0.15, 0.15)	79 (33,80)	79 (78,82)	72 (29,79)	79 (78,82)
(0.2, 0.2)	31 (30,32)	54 (51,72)	29 (28,30)	44 (42,72)